Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.54 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367036 | 1.00 | ELANE (0.54) | ELANEF2CTSGNPC1RAB9A | |
| SCHEMBL21358337 | 1.00 | ELANE (0.54) | ELANEF2CTSGNPC1RAB9A | |
| SCHEMBL31367113 | 1.00 | ELANE (0.54) | ELANEF2CTSGNPC1RAB9A | |
| SCHEMBL30591216 | 0.87 | ELANE (0.52) | ELANEF2CTSGNPC1RAB9A | |
| SCHEMBL17428773 | 0.87 | ELANE (0.52) | ELANEF2CTSGNPC1RAB9A | |
| SCHEMBL30591356 | 0.86 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2FKBP1ANPSR1 | |
| SCHEMBL30591394 | 0.86 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2FKBP1ANPSR1 | |
| SCHEMBL30591324 | 0.85 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2FKBP1ANPSR1 | |
| SCHEMBL8284648 | 0.85 | FKBP1A (0.48) | ELANENPC1RAB9ASMN1; SMN2FKBP1A | |
| SCHEMBL23270785 | 0.83 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2FKBP1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-02-11 | — | — | US | disclosed |
| EP-3765006-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp&Dohme Corp. (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019177873-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019177873-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ELANE 160/4885F2 1622/4885CTSG 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.